<p>Telix Pharmaceuticals NASDAQ: TLX 举办了一场教育网络研讨会，概述了其下一代前列腺特异性膜抗原（PSMA）放射药物策略，管理层和临床研究者强调了在前列腺癌治疗中，患者中心化剂量和改善耐受性的重要性。</p>
<p>获取 <strong>Telix Pharmaceuticals</strong> 的提醒：</p>
<p>本次会议由 <strong>Stewart Holmstrom</strong> 主持，他是 Telix 的企业传播总监，参与者包括 <strong>Dr. David Cade</strong>，Telix 集团首席医学官，以及特邀讲者 <strong>Professor Louise Emmett</strong>，她是悉尼圣文森特医院的治疗学与核医学主任，同时也是 OPTIMAL-PSMA 试验的首席研究员。</p>
<h2>放射配体治疗与 Telix 的产品组合策略</h2>
<p>Dr. Cade 回顾了放射配体治疗在晚期转移性去势抵抗性前列腺癌（mCRPC）中的确立，指出 PSMA-617（诺华的 Pluvicto）及其 VISION 试验结果的作用，他表示该结果显示与传统标准治疗相比，整体生存期延长了四个月。</p>
<p>他还描述了在转移性激素敏感性前列腺癌（mHSPC）中更早使用放射配体治疗的日益关注，同时强调了在身体状况较好的患者中观察到的一代小分子放射配体的挑战。Dr. Cade 表示，出现的担忧包括唾液腺辐射暴露导致口干和生活质量影响，以及肾脏辐射暴露可能导致长期肾损伤。</p>
<p>在此背景下，Dr. Cade 概述了 Telix 的产品组合策略，采用 “非常独特的作用机制”，包括：</p>
<ul>
<li><strong>TLX591</strong>，一种正在进行的 3 期 <strong>ProstACT Global</strong> 试验中研究的放射抗体药物结合物，针对晚期 mCRPC。</li>
<li><strong>TLX597-Tx</strong>，一种二代小分子放射配体治疗，Dr. Cade 表示其显示出 “非常低的唾液腺和肾脏剂量”，同时肿瘤剂量较高，这使其适合在 mHSPC 中更早使用和剂量强化策略。</li>
</ul>
<h2>OPTIMAL-PSMA：测试剂量强化和优化</h2>
<p>Professor Emmett 介绍了 <strong>OPTIMAL-PSMA</strong> 的理论基础和早期经验，这是一个随机的 2 期试验，比较剂量强化与标准剂量。她将该试验框架描述为解决她所称的挫折，即常见的镥-177 PSMA 方案是围绕外部放射肾脏限制而非疗效构建的，而整体生存期的提升难以证明。</p>
<p>Professor Emmett 表示，该试验旨在评估早期短期强化剂量是否能够 “在癌细胞最脆弱时攻击它们”，随后进行后续的 “维持治疗”。她将其生物学理论描述为结合（1）辐射引起的 DNA 损伤后 PSMA 的上调和（2）在 DNA 修复完全解决之前的剂量时机，可能通过治疗已经受损的细胞产生 “更深的打击”。</p>
<p>在试验中，患者为 mCRPC，必须已对雄激素受体通路抑制剂（ARPI）和多西他赛治疗失败，或不适合多西他赛；她指出，许多入组患者已对一或两种化疗失败。她将该队列描述为高负荷且经过重度预处理，指出试验的广泛纳入标准部分是由于在澳大利亚对镥-177 PSMA 治疗的有限获取。</p>
<h2>剂量测定和早期耐受性观察</h2>
<p>Professor Emmett 强调了来自安全性引导队列（前 12 名患者）的剂量测定结果，将 TLX597-Tx 与 PSMA-617 和 PSMA I&amp;T 的先前出版物进行了比较。她报告了 <strong>0.28 gray 每千兆贝可勒尔</strong> 的肾脏剂量，而参考比较中的剂量为 <strong>0.58</strong> 和 <strong>0.71</strong>，并表示泪腺和唾液腺的活性 “显著较低”，而肿瘤活性得以维持。</p>
<p>她还描述了在接受 7.5 千兆贝可勒尔 TLX597-Tx 剂量后的序列 SPECT/CT 成像时间点，指出在注射后 120 小时，肿瘤信号仍然明亮，而唾液腺和肾脏则难以可视化，部分原因归因于肠道排泄。</p>
<p>在安全性方面，Professor Emmett 表示迄今为止的毒性较低，包括对前 10 名接受剂量强化方案治疗的患者进行的 10 周后数据安全监测委员会审查。她报告了五例 1 级贫血，两例 1 级血小板增多症，一例 1 级口干症和两例 3 级淋巴细胞减少症。她补充说，在高负荷疾病中，疼痛可能在头几周加重，她的团队使用疼痛规划和地塞米松来减轻疲劳。</p>
<h2>入组更新和早期疾病的计划（OPTIMAL-E）</h2>
<p>Professor Emmett 表示 OPTIMAL-PSMA 正在接近完成入组，目前大约 <strong>90 名中的 120 名</strong> 患者已被随机分配，主要在悉尼圣文森特医院的一个地点。她补充说，接受的中位剂量为四次，因为通常在此时会发生进展，她表示大约 45% 的患者在第三次剂量时已发生进展——称这是未来努力中 “需要克服的事情”，以使患者在治疗中停留更长时间。</p>
<p>展望早期 mHSPC，Professor Emmett 描述了 <strong>OPTIMAL-E</strong>，这是一个结合了强化剂量与 ARPI 和雄激素剥夺治疗（ADT）的概念，随后进行 PSMA PET 引导的适应性剂量。如果在 12 周的 PSMA PET 扫描中未发现疾病，则镥-177 PSMA 治疗将停止，而 ARPI 和 ADT 将继续，首次确认 PSA 上升时将触发再治疗。她表示希望看到高比例的患者在关键时间点达到 PSA 低于 0.2 且 PSMA PET 上没有残余疾病，同时保持生活质量并避免过度治疗。</p>
<p>在问答环节中，Cade 博士回应了关于血液毒性和胃肠道影响的问题，表示早期剂量分布特征表明在包括骨髓在内的器官中，非靶向剂量较低，并且报告给独立监测委员会的观察到的不良事件特征与其他小分子相比，相关的全身性副作用相对较低。</p>
<p>网络研讨会结束时，Telix 重申了其在机制、剂量策略和耐受性与疾病阶段之间对齐的重要性，Emmett 教授也承认该试验在扩大新南威尔士州患者治疗获取方面的作用。</p>
<h2>关于 Telix Pharmaceuticals NASDAQ: TLX</h2>
<p>Telix Pharmaceuticals NASDAQ: TLX 是一家临床阶段的生物制药公司，专注于分子靶向放射药物的开发和商业化，以用于癌症的诊断和治疗。Telix 利用在放射化学、核医学和肿瘤学方面的专业知识，旨在通过将诊断成像剂与治疗性放射性核素相结合，解决多种肿瘤类型未满足的临床需求。</p>
<p>该公司的产品线涵盖了成像和治疗候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比 Telix Pharmaceuticals 更好的股票</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Telix Pharmaceuticals 吗？</h2>
<p>在考虑 Telix Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Telix Pharmaceuticals 并不在名单上。</p>
<p>虽然 Telix Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Telix Pharmaceuticals 举办了一场网络研讨会，讨论其下一代 PSMA 放射药物策略，强调以患者为中心的给药和耐受性。David Cade 博士强调了放射配体治疗在晚期前列腺癌中的作用以及第一代疗法面临的挑战。Louise Emmett 教授介绍了 OPTIMAL-PSMA 试验，重点关注剂量强化以提高疗效。该试验即将完成，目前已招募 120 名患者中的 90 名，旨在改善转移性激素敏感性前列腺癌的治疗。初步结果显示新疗法在安全性和耐受性方面表现良好</p>

<p>Telix Pharmaceuticals NASDAQ: TLX hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical investigator emphasizing the need for more patient-centric dosing and improved tolerability as PSMA-targeted therapy moves earlier in prostate cancer care.</p>
<div class="lb-trans"><p>Telix Pharmaceuticals NASDAQ: TLX 举办了一场教育网络研讨会，概述了其下一代前列腺特异性膜抗原（PSMA）放射药物策略，管理层和临床研究者强调了在前列腺癌治疗中，患者中心化剂量和改善耐受性的重要性。</p>
</div><p>Get <strong>Telix Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Telix Pharmaceuticals</strong> 的提醒：</p>
</div><p>The session was moderated by <strong>Stewart Holmstrom</strong>, Telix’s Director of Corporate Communications, and featured <strong>Dr. David Cade</strong>, Telix Group Chief Medical Officer, alongside guest speaker <strong>Professor Louise Emmett</strong>, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital Sydney and Principal Investigator of the OPTIMAL-PSMA trial.</p>
<div class="lb-trans"><p>本次会议由 <strong>Stewart Holmstrom</strong> 主持，他是 Telix 的企业传播总监，参与者包括 <strong>Dr. David Cade</strong>，Telix 集团首席医学官，以及特邀讲者 <strong>Professor Louise Emmett</strong>，她是悉尼圣文森特医院的治疗学与核医学主任，同时也是 OPTIMAL-PSMA 试验的首席研究员。</p>
</div><h2>Positioning radioligand therapy and Telix’s portfolio approach</h2>
<div class="lb-trans"><h2>放射配体治疗与 Telix 的产品组合策略</h2>
</div><p>Dr. Cade reviewed how radioligand therapy has established itself in advanced metastatic castration-resistant prostate cancer (mCRPC), pointing to the role of PSMA-617 (Novartis’ Pluvicto) and its VISION trial results, which he said showed a four-month overall survival extension compared with conventional standard of care.</p>
<div class="lb-trans"><p>Dr. Cade 回顾了放射配体治疗在晚期转移性去势抵抗性前列腺癌（mCRPC）中的确立，指出 PSMA-617（诺华的 Pluvicto）及其 VISION 试验结果的作用，他表示该结果显示与传统标准治疗相比，整体生存期延长了四个月。</p>
</div><p>He also described growing interest in deploying radioligand therapy earlier, in metastatic hormone-sensitive prostate cancer (mHSPC), while highlighting challenges observed with first-generation small-molecule radioligands in fitter patients. Dr. Cade said emerging concerns include salivary gland radiation exposure leading to dry mouth and quality-of-life impacts, as well as kidney radiation exposure that could contribute to long-term renal injury.</p>
<div class="lb-trans"><p>他还描述了在转移性激素敏感性前列腺癌（mHSPC）中更早使用放射配体治疗的日益关注，同时强调了在身体状况较好的患者中观察到的一代小分子放射配体的挑战。Dr. Cade 表示，出现的担忧包括唾液腺辐射暴露导致口干和生活质量影响，以及肾脏辐射暴露可能导致长期肾损伤。</p>
</div><p>Against that backdrop, Dr. Cade outlined Telix’s portfolio strategy using “very distinct mechanisms of action,” including:</p>
<div class="lb-trans"><p>在此背景下，Dr. Cade 概述了 Telix 的产品组合策略，采用 “非常独特的作用机制”，包括：</p>
</div><ul>
<li><strong>TLX591</strong>, a radioantibody-drug conjugate being studied in advanced mCRPC in the ongoing Phase 3 <strong>ProstACT Global</strong> trial.</li>
<li><strong>TLX597-Tx</strong>, a second-generation small-molecule radioligand therapy that Dr. Cade said has shown “very minimal salivary gland and kidney dose” alongside a high tumor dose, which he said could make it suitable for earlier use in mHSPC and for dose intensification strategies.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>TLX591</strong>，一种正在进行的 3 期 <strong>ProstACT Global</strong> 试验中研究的放射抗体药物结合物，针对晚期 mCRPC。</li>
<li><strong>TLX597-Tx</strong>，一种二代小分子放射配体治疗，Dr. Cade 表示其显示出 “非常低的唾液腺和肾脏剂量”，同时肿瘤剂量较高，这使其适合在 mHSPC 中更早使用和剂量强化策略。</li>
</ul>
</div><h2>OPTIMAL-PSMA: testing dose intensification and optimization</h2>
<div class="lb-trans"><h2>OPTIMAL-PSMA：测试剂量强化和优化</h2>
</div><p>Professor Emmett presented the rationale and early experience from <strong>OPTIMAL-PSMA</strong>, a randomized Phase 2 trial comparing dose intensification versus standard dosing. She framed the trial as an effort to address what she described as frustration that common Lutetium-177 PSMA schedules were built around external beam kidney constraints rather than efficacy, while overall survival gains have been difficult to demonstrate.</p>
<div class="lb-trans"><p>Professor Emmett 介绍了 <strong>OPTIMAL-PSMA</strong> 的理论基础和早期经验，这是一个随机的 2 期试验，比较剂量强化与标准剂量。她将该试验框架描述为解决她所称的挫折，即常见的镥-177 PSMA 方案是围绕外部放射肾脏限制而非疗效构建的，而整体生存期的提升难以证明。</p>
</div><p>Professor Emmett said the trial is designed to evaluate whether short, intensified dosing early can “attack the cancer cells when they're most vulnerable,” followed by later “maintenance.” She described the underlying biological thesis as combining (1) PSMA upregulation following radiation-induced DNA damage and (2) timing doses before DNA repair has fully resolved, potentially producing a “deeper hit” by treating already damaged cells.</p>
<div class="lb-trans"><p>Professor Emmett 表示，该试验旨在评估早期短期强化剂量是否能够 “在癌细胞最脆弱时攻击它们”，随后进行后续的 “维持治疗”。她将其生物学理论描述为结合（1）辐射引起的 DNA 损伤后 PSMA 的上调和（2）在 DNA 修复完全解决之前的剂量时机，可能通过治疗已经受损的细胞产生 “更深的打击”。</p>
</div><p>In the trial, patients have mCRPC and must have failed an androgen receptor pathway inhibitor (ARPI) and failed docetaxel or be docetaxel-ineligible; she noted many enrolled patients have failed one or two lines of chemotherapy. She described the cohort as high-volume and heavily pre-treated, noting the trial’s broad inclusion criteria were partly driven by limited access to Lutetium-177 PSMA therapy in Australia.</p>
<div class="lb-trans"><p>在试验中，患者为 mCRPC，必须已对雄激素受体通路抑制剂（ARPI）和多西他赛治疗失败，或不适合多西他赛；她指出，许多入组患者已对一或两种化疗失败。她将该队列描述为高负荷且经过重度预处理，指出试验的广泛纳入标准部分是由于在澳大利亚对镥-177 PSMA 治疗的有限获取。</p>
</div><h2>Dosimetry and early tolerability observations</h2>
<div class="lb-trans"><h2>剂量测定和早期耐受性观察</h2>
</div><p>Professor Emmett highlighted dosimetry findings from the safety lead-in cohort (the first 12 patients), comparing TLX597-Tx with prior publications for PSMA-617 and PSMA I&amp;T. She reported a kidney dose of <strong>0.28 gray per gigabecquerel</strong>, compared with <strong>0.58</strong> and <strong>0.71</strong> in the referenced comparators, and said lacrimal and salivary gland activity was “significantly lower” while tumoral activity was maintained.</p>
<div class="lb-trans"><p>Professor Emmett 强调了来自安全性引导队列（前 12 名患者）的剂量测定结果，将 TLX597-Tx 与 PSMA-617 和 PSMA I&amp;T 的先前出版物进行了比较。她报告了 <strong>0.28 gray 每千兆贝可勒尔</strong> 的肾脏剂量，而参考比较中的剂量为 <strong>0.58</strong> 和 <strong>0.71</strong>，并表示泪腺和唾液腺的活性 “显著较低”，而肿瘤活性得以维持。</p>
</div><p>She also described serial SPECT/CT imaging timepoints after a 7.5 gigabecquerel dose of TLX597-Tx, noting that by 120 hours post-injection, tumor signal remained bright while salivary glands and kidneys were difficult to visualize, attributing part of the profile to bowel excretion.</p>
<div class="lb-trans"><p>她还描述了在接受 7.5 千兆贝可勒尔 TLX597-Tx 剂量后的序列 SPECT/CT 成像时间点，指出在注射后 120 小时，肿瘤信号仍然明亮，而唾液腺和肾脏则难以可视化，部分原因归因于肠道排泄。</p>
</div><p>On safety, Professor Emmett said toxicity to date has been low, including a data safety monitoring board review (after 10 weeks) of the first 10 patients treated with a dose-intensified regimen. She reported five grade 1 anemias, two grade 1 thrombocythemias, one grade 1 xerostomia, and two grade 3 lymphopenias. She added that in high-volume disease, pain can worsen in the first couple of weeks, and her team uses pain planning and dexamethasone to mitigate fatigue.</p>
<div class="lb-trans"><p>在安全性方面，Professor Emmett 表示迄今为止的毒性较低，包括对前 10 名接受剂量强化方案治疗的患者进行的 10 周后数据安全监测委员会审查。她报告了五例 1 级贫血，两例 1 级血小板增多症，一例 1 级口干症和两例 3 级淋巴细胞减少症。她补充说，在高负荷疾病中，疼痛可能在头几周加重，她的团队使用疼痛规划和地塞米松来减轻疲劳。</p>
</div><h2>Enrollment update and plans for earlier disease (OPTIMAL-E)</h2>
<div class="lb-trans"><h2>入组更新和早期疾病的计划（OPTIMAL-E）</h2>
</div><p>Professor Emmett said OPTIMAL-PSMA was approaching completion of enrollment, with roughly <strong>90 of 120</strong> patients randomized, largely at a single site at St Vincent’s Hospital Sydney. She added that the median number of doses received was four because progression commonly occurred around that time, and she said about 45% of patients had progressed by dose three—calling that “the thing to beat” in future efforts to keep patients on therapy longer.</p>
<div class="lb-trans"><p>Professor Emmett 表示 OPTIMAL-PSMA 正在接近完成入组，目前大约 <strong>90 名中的 120 名</strong> 患者已被随机分配，主要在悉尼圣文森特医院的一个地点。她补充说，接受的中位剂量为四次，因为通常在此时会发生进展，她表示大约 45% 的患者在第三次剂量时已发生进展——称这是未来努力中 “需要克服的事情”，以使患者在治疗中停留更长时间。</p>
</div><p>Looking to earlier mHSPC, Professor Emmett described <strong>OPTIMAL-E</strong>, a concept using intensive dosing up front combined with ARPI and androgen deprivation therapy (ADT), followed by PSMA PET-guided adaptive dosing. If disease is absent on a 12-week PSMA PET scan, Lutetium-177 PSMA therapy would stop while ARPI and ADT continue, with retreatment triggered at first confirmed PSA rise. She said she would like to see a high proportion of patients reaching a PSA below 0.2 and no residual disease on PSMA PET at key timepoints, while maintaining quality of life and avoiding overtreatment.</p>
<div class="lb-trans"><p>展望早期 mHSPC，Professor Emmett 描述了 <strong>OPTIMAL-E</strong>，这是一个结合了强化剂量与 ARPI 和雄激素剥夺治疗（ADT）的概念，随后进行 PSMA PET 引导的适应性剂量。如果在 12 周的 PSMA PET 扫描中未发现疾病，则镥-177 PSMA 治疗将停止，而 ARPI 和 ADT 将继续，首次确认 PSA 上升时将触发再治疗。她表示希望看到高比例的患者在关键时间点达到 PSA 低于 0.2 且 PSMA PET 上没有残余疾病，同时保持生活质量并避免过度治疗。</p>
</div><p>During Q&amp;A, Dr. Cade responded to questions on hematologic toxicity and gastrointestinal effects, saying the early dosimetry profile suggests low off-target dose in organs including bone marrow and that the observed adverse-event profile reported to the independent monitoring committee included relatively low constitutional side effects compared with other small molecules.</p>
<div class="lb-trans"><p>在问答环节中，Cade 博士回应了关于血液毒性和胃肠道影响的问题，表示早期剂量分布特征表明在包括骨髓在内的器官中，非靶向剂量较低，并且报告给独立监测委员会的观察到的不良事件特征与其他小分子相比，相关的全身性副作用相对较低。</p>
</div><p>The webinar concluded with Telix reiterating its emphasis on aligning mechanism, dosing strategy, and tolerability with disease stage, and with Professor Emmett acknowledging the trial’s role in expanding treatment access for patients across New South Wales.</p>
<div class="lb-trans"><p>网络研讨会结束时，Telix 重申了其在机制、剂量策略和耐受性与疾病阶段之间对齐的重要性，Emmett 教授也承认该试验在扩大新南威尔士州患者治疗获取方面的作用。</p>
</div><h2>About Telix Pharmaceuticals NASDAQ: TLX</h2>
<div class="lb-trans"><h2>关于 Telix Pharmaceuticals NASDAQ: TLX</h2>
</div><p>Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.</p>
<div class="lb-trans"><p>Telix Pharmaceuticals NASDAQ: TLX 是一家临床阶段的生物制药公司，专注于分子靶向放射药物的开发和商业化，以用于癌症的诊断和治疗。Telix 利用在放射化学、核医学和肿瘤学方面的专业知识，旨在通过将诊断成像剂与治疗性放射性核素相结合，解决多种肿瘤类型未满足的临床需求。</p>
</div><p>The company’s pipeline spans both imaging and therapeutic candidates.</p>
<div class="lb-trans"><p>该公司的产品线涵盖了成像和治疗候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Telix Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Telix Pharmaceuticals 更好的股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Telix Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Telix Pharmaceuticals 吗？</h2>
</div><p>Before you consider Telix Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Telix Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Telix Pharmaceuticals 并不在名单上。</p>
</div><p>While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Telix Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End

Market Beat

Telix Pharmaceuticals 网络研讨会重点介绍下一代 PSMA 疗法，OPTIMAL-PSMA 的招募工作接近尾声